See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Power Outages
Pope Francis
Donald Trump
US Politics
Social Media
Artificial Intelligence
Democratic Party
NFL
Baseball
Natural Disasters
Republican Party
Vatican
Published • loading... • Updated

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Summary by Barchart.com
Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Barchart.comBarchart.com

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Barchart.com broke the news in on Thursday, March 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Eli Lilly

Eli Lilly

Thousand Oaks

Thousand Oaks

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal